NIAID Partnerships with Product Development Public-Private Partnerships (R01)

The summary for the NIAID Partnerships with Product Development Public-Private Partnerships (R01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

NIAID Partnerships with Product Development Public-Private Partnerships (R01): Purpose. This Funding Opportunity Announcement (FOA) issued by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), seeks research project grant (R01) applications from established, not-for-profit product development Public-Private Partnerships (PD PPPs) in order to accelerate preclinical research and development of promising preventive, therapeutic, or diagnostic tools, or vector management strategies for neglected infectious diseases. PD PPPs should have a track record of development of interventions for neglected infectious diseases of global importance, and highest prevalence in low income countries for which commercial markets provide insufficient incentives for product development. These diseases include malaria, tuberculosis, Neglected Tropical Diseases (see the following link for a list of NTDs: http://www3.niaid.nih.gov/topics/tropicalDiseases/research/examples.htm), and, where relevant, their vectors. Projects must include milestones and timelines to support projects on various aspects of preclinical development and IND enabling studies (e.g. validation of targets for intervention, process development, formulation, toxicology etc.) as well as a product development plan. Mechanism of Support. This FOA will utilize the R01 grant mechanism. Funds Available and Anticipated Number of Awards. NIAID expects to award $3.7 million in total costs in response to this FOA in FY 2010; the anticipated number of awards is 5-8.

Federal Grant Title:	NIAID Partnerships with Product Development Public-Private Partnerships (R01)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-AI-09-034
Type of Funding:	Grant
CFDA Numbers:	93.856
CFDA Descriptions:	Microbiology and Infectious Diseases Research
Current Application Deadline:	Oct 30, 2009
Original Application Deadline:	Oct 30, 2009
Posted Date:	Jul 15, 2009
Creation Date:	Jul 15, 2009
Archive Date:	Nov 30, 2009
Total Program Funding:	$3,700,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Public and State controlled institutions of higher education - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Non-domestic (non-U.S.) Entities (Foreign Organizations); Tribally Controlled Colleges and Universities (TCCUs) .
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants: • Biomedical Prevention of HIV Research Education (R25); • Partnerships for Next Generation Biodefense Diagnostics (R01); • National Biocontainment Laboratories (NBLs) Operations Support Limited Competition (UC7); • Partnerships for Development of New Therapeutic Classes for Select Viral and Bacterial Pat...; • Non-Antibiotic Selectable Markers for Biodefense (R21); • Partnerships to Improve Diagnosis and Treatment of Selected Drug-Resistant Healthcare-Asso...; • Cooperative Research Partnerships for Biodefense (U01)
More Grants from the National Institutes of Health: • SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies...; • Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Al...; • Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional); • Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial No...; • Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimenta...